Semax

CAS NO: 80714-61-0
Molecular Formula: C37H51N9O10S
Molecular Weight: 813.929 g/mol
Appearance: white powder
Storage: 2-8°
Purity: ≥99%

Semax is a synthetic heptapeptide that is an analog of the N-terminal fragment (4-10) of adrenocorticotropic hormone (ACTH). This peptide, which comprises the sequence 4-7 of the N-terminal domain of ACTH and a C-terminal Pro-Gly-Pro tripeptide, has been extensively studied for its various neuroprotective and nootropic (cognitive-enhancing) effects. Below is a summary of key research findings on Semax, along with the respective citations:

1. Cognitive Enhancement and Neuroprotection: Semax is found to stimulate memory and attention in both rodents and humans following intranasal application. It exerts a marked impact on learning processes and cognitive brain functions, and it has been observed to have profound effects on learning and memory formation (Semenova, T. P., et al. “Semax, an analogue of adrenocorticotropin (4-10), is a…” Neuropeptides, vol. 38, no. 6, 2004, pp. 377-383. DOI: 10.1016/j.npep.2004.09.005).
2. Neurotropic and Analgesic Effects: Semax has been shown to have prolonged neurotropic activity and can influence learning capabilities and pain sensitivity in animals. This is significant in the context of its potential therapeutic uses in neuropathic conditions (Kolik, L. G., et al. “[Nootropic and analgesic effects of Semax following different…” Experimental and Clinical Pharmacology, vol. 67, no. 5, 2004, pp. 56-59. DOI: 10.1007/s11094-005-0065-2).
3. Impact on Neuronal Networks: Research involving resting state functional magnetic resonance imaging (fMRI) has explored the effects of Semax on the neuronal network of the brain. Such studies are crucial in understanding how Semax impacts brain connectivity and function at a macroscopic level (Kalinichenko, L. S., et al. “Functional Connectomic Approach to Studying Selank and Semax…” Neuropsychobiology, vol. 77, no. 4, 2018, pp. 201-210. DOI: 10.1159/000487413).
4. Treatment of Brain Blood Circulation Disorders: Semax has been successfully used in clinical practice for treating severe brain blood circulation disorders. Its efficacy in this domain underscores its potential in managing various cerebrovascular conditions (Gusev, E. I., et al. “The effect of Semax and its C-end peptide PGP on the…” Neuroscience and Behavioral Physiology, vol. 35, no. 9, 2005, pp. 871-875. DOI: 10.1007/s11055-005-0135-z).
5. Neuroprotective Mechanism in Ischemic Stroke: As a synthetic melanocortin derivative, Semax has been used in the treatment of ischemic stroke. Studies have shown that it enhances the transcription of neurotrophins and their receptors, thus playing a significant role in neuroprotection during cerebral ischemia (Ashmarin, I. P., et al. “Brain Protein Expression Profile Confirms the Protective…” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 3, 2007, pp. 478-488. DOI: 10.1038/sj.jcbfm.9600366).

In summary, Semax demonstrates a wide range of neuroprotective and cognitive-enhancing effects, with applications in treating brain disorders, improving cognitive functions, managing pain, and aiding in the recovery of neurological conditions. Its utility extends from enhancing memory and attention to treating severe brain blood circulation disorders and optic nerve diseases. Furthermore, its impact on brain-derived neurotrophic factor (BDNF) levels indicates its significant role in neuroplasticity and rehabilitation processes. These diverse therapeutic applications of Semax, backed by substantial research, highlight its potential as a valuable pharmacological agent in neurology and psychiatry. However, despite the promising findings, there remains a significant scope for further research to fully understand and harness Semax’s therapeutic potential.

Please note that all products featured here are intended exclusively for research and development purposes. They are not designed for any form of human consumption. These products have not undergone evaluation by the U.S. Food and Drug Administration.